Fishman Jay A Ltd. MI Cuts Holdings in Pfizer Inc. $PFE

Fishman Jay A Ltd. MI lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 22.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 197,270 shares of the biopharmaceutical company’s stock after selling 55,687 shares during the period. Pfizer makes up 0.5% of Fishman Jay A Ltd. MI’s portfolio, making the stock its 28th biggest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $5,539,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. State Street Corp lifted its position in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after buying an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC lifted its position in Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares in the last quarter. Morgan Stanley grew its stake in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares during the period. Finally, Norges Bank purchased a new position in shares of Pfizer in the 4th quarter valued at $1,830,986,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being highlighted by multiple value-oriented articles as a cheap healthcare stock, with some analysts and commentators arguing the shares may offer upside at current levels for investors seeking income and defensive exposure. 2 Dirt Cheap Healthcare Stocks to Buy in July
• Positive Sentiment: Pfizer won FDA approval for IBRANCE in HER2-positive breast cancer, adding a fresh regulatory win and another potential use case for one of its key oncology drugs. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Cantor Fitzgerald reaffirmed a neutral rating but maintained a $27 price target, implying upside from current levels and signaling that Wall Street still sees valuation support. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Pfizer is drawing attention as a high-yield dividend stock, but several articles frame the yield as a sign of investor caution rather than a clear bullish catalyst. 2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them
• Neutral Sentiment: Analysts are still debating Pfizer’s long-term growth prospects versus peers like AstraZeneca, suggesting the market remains uncertain about the pace of future expansion. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Neutral Sentiment: Pfizer also received renewed scrutiny over its dividend sustainability, with some commentary warning investors to read the “fine print” on the payout. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think
• Negative Sentiment: Pfizer was downgraded to Hold, with analysts citing delayed pipeline catalysts, leadership changes, and reduced near-term re-rating potential. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
• Negative Sentiment: One market recap said Pfizer fell while the broader market rose, underscoring ongoing pressure tied to concerns about growth and sentiment. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PFE. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Monday. Guggenheim increased their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Finally, CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.59.

Pfizer Price Performance

PFE stock opened at $24.04 on Wednesday. The stock’s 50 day moving average is $25.51 and its two-hundred day moving average is $26.21. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a market capitalization of $137.00 billion, a PE ratio of 18.35 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer’s payout ratio is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.